Novartis Heart Drug Trial Does Not Meet Goal
A new drug from Novartis did not help patients avoid heart attacks or strokes in its most important test.
Many people look to new medicines to fight heart disease. Novartis worked on a drug to lower Lp(a), a special fat in the blood. Doctors believed lowering this fat could stop heart attacks and strokes. The drug entered its final testing stage.
The trial results are now out. The drug did lower the Lp(a) levels as planned. But it did not stop people from having heart problems. Patients still faced the same risk of heart attacks and strokes. This news is a setback for fighting heart disease.
Researchers are still learning about Lp(a) and heart health. This trial shows that lowering Lp(a) might not be enough on its own. Scientists will keep working to find new ways to protect hearts. This work remains important for everyone.
Source: FierceBiotech
More from Biotech
